Key use cases for artificial intelligence to reduce the frequency of adverse drug events: a scoping review
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Adverse drug events (ADEs) represent one of the most prevalent types of health-care-related harm, and there is substantial room for improvement in the way that they are currently predicted and detected. We conducted a scoping review to identify key use cases in which artificial intelligence (AI) could be leveraged to reduce the frequency of ADEs. We focused on modern machine learning techniques and natural language processing. 78 articles were included in the scoping review. Studies were heterogeneous and applied various AI techniques covering a wide range of medications and ADEs. We identified several key use cases in which AI could contribute to reducing the frequency and consequences of ADEs, through prediction to prevent ADEs and early detection to mitigate the effects. Most studies (73 [94%] of 78) assessed technical algorithm performance, and few studies evaluated the use of AI in clinical settings. Most articles (58 [74%] of 78) were published within the past 5 years, highlighting an emerging area of study. Availability of new types of data, such as genetic information, and access to unstructured clinical notes might further advance the field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
Tricco, A. C., Lillie, E., Zarin, W., O'Brien, K. K., Colquhoun, H., Levac, D., Moher, D., Peters, M. D. J., Horsley, T., Weeks, L., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0850 · Cited by 43,565
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention
Bates, D. W. (1995) · JAMA · doi:10.1001/jama.1995.03530010043033 · Cited by 2,127
Self-citationEvaluating artificial intelligence in medicine: phases of clinical research
Park, Y., Jackson, G. P., Foreman, M. A., Gruen, D., Hu, J., & Das, A. K. (2020) · JAMIA Open · doi:10.1093/jamiaopen/ooaa033 · Cited by 150
Self-citation
Cited by
Singh, S., Kumar, R., Payra, S., & Singh, S. K. (2023) · Cureus · doi:10.7759/cureus.44359 · Cited by 154
A scoping review on generative AI and large language models in mitigating medication related harm
Ong, J. C. L., Chen, M. H., Ng, N., Elangovan, K., Tan, N. Y. T., Jin, L., Xie, Q., Ting, D. S. W., Rodriguez-Monguio, R., Bates, D. W., et al. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01565-7 · Cited by 64
Self-citation(2023) · doi:10.2196/51921 · Cited by 37
Introduction to Drug Safety and Pharmacovigilance
Jose, J., Cox, A. R., & Bate, A. (2024) · Principles and Practice of Pharmacovigilance and Drug Safety · doi:10.1007/978-3-031-51089-2_1 · Cited by 3
Metadata
- Authors
- Syrowatka, A., Song, W., Amato, M. G., Foer, D., Edrees, H., Co, Z., Kuznetsova, M., Dulgarian, S., Seger, D. L., Simona, A., Bain, P. A., Purcell Jackson, G., Rhee, K., & Bates, D. W.
- Venue
- The Lancet Digital Health
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 4
- Issue
- 2
- Pages
- e137-e148
- ISSN
- 2589-7500 (ISSN-L)
- OpenAlex
- W3217124584
- Cited by
- 94
- References
- 4
- FWCI
- 27.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Key use cases for artificial intelligence to reduce the frequency of adverse drug events: a scoping review. https://app.cochat.ai/papers/10.1016/s2589-7500(21)00229-6
- The paper
- Syrowatka, A., Song, W., Amato, M. G., Foer, D., Edrees, H., Co, Z., Kuznetsova, M., Dulgarian, S., Seger, D. L., Simona, A., Bain, P. A., Purcell Jackson, G., Rhee, K., & Bates, D. W. (2022). Key use cases for artificial intelligence to reduce the frequency of adverse drug events: a scoping review. The Lancet Digital Health. https://doi.org/10.1016/s2589-7500(21)00229-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.